Inventory increased 8.9%
Inventory changed +8.9% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
$4.5B→$4.9B4 prior comparisons
GROSSPATTERN / DETERMINISTIC EVIDENCE / V3
Search securities →TXT financial changes
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Operating cash flow increased 21.8%
Operating cash flow changed +21.8% from the comparable as-filed period.
$349.0M→$425.0M2 prior comparisons
Free-cash-flow proxy increased 18.3%
Free-cash-flow proxy changed +18.3% from the comparable as-filed period.
$273.0M→$323.0M2 prior comparisons
Inventory / revenue moved 566 bp higher
Inventory / revenue changed +566 basis points from the comparable as-filed period.
123.93%→129.59%2 prior comparisons
Capital expenditure increased 34.2%
Capital expenditure changed +34.2% from the comparable as-filed period.
$76.0M→$102.0M3 prior comparisons
Revenue increased 4.1%
Revenue changed +4.1% from the comparable as-filed period.
$3.6B→$3.8B2 prior comparisons
Net income increased 15.4%
Net income changed +15.4% from the comparable as-filed period.
$234.0M→$270.0M2 prior comparisons
Capex / revenue moved 61 bp higher
Capex / revenue changed +61 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
2.11%→2.72%2 prior comparisons
Total assets increased 5.6%
Total assets changed +5.6% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
$17.4B→$18.3B4 prior comparisons
Shares outstanding decreased 3.9%
Shares outstanding changed -3.9% from the comparable as-filed period. The change ranks at the 25th percentile of 8 prior comparable changes.
176,224,064→169,399,9798 prior comparisons
Operating cash-flow margin moved 164 bp higher
Operating cash-flow margin changed +164 basis points from the comparable as-filed period.
9.69%→11.33%2 prior comparisons
Free-cash-flow margin moved 103 bp higher
Free-cash-flow margin changed +103 basis points from the comparable as-filed period.
7.58%→8.61%2 prior comparisons
Research & development decreased 6.8%
Research & development changed -6.8% from the comparable as-filed period.
$118.0M→$110.0M2 prior comparisons
R&D / revenue moved 34 bp lower
R&D / revenue changed -34 basis points from the comparable as-filed period.
3.28%→2.93%2 prior comparisons
Operating cash flow / net income increased 5.5%
Operating cash flow / net income changed +5.5% from the comparable as-filed period.
1.49→1.572 prior comparisons
Selling, general & administrative increased 5.4%
Selling, general & administrative changed +5.4% from the comparable as-filed period.
$257.0M→$271.0M2 prior comparisons
Inventory increased 8.8%
Inventory changed +8.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
$4.3B→$4.7B4 prior comparisons
Free-cash-flow proxy decreased 32.4%
Free-cash-flow proxy changed -32.4% from the comparable as-filed period.
$309.0M→$209.0M2 prior comparisons
Operating cash flow decreased 21.4%
Operating cash flow changed -21.4% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
$387.0M→$304.0M3 prior comparisons
Inventory / revenue moved 660 bp higher
Inventory / revenue changed +660 basis points from the comparable as-filed period.
116.74%→123.33%2 prior comparisons
Revenue increased 3.0%
Revenue changed +3.0% from the comparable as-filed period.
$3.7B→$3.8B2 prior comparisons
Free-cash-flow margin moved 285 bp lower
Free-cash-flow margin changed -285 basis points from the comparable as-filed period.
8.32%→5.46%2 prior comparisons
Operating cash-flow margin moved 247 bp lower
Operating cash-flow margin changed -247 basis points from the comparable as-filed period.
10.41%→7.94%2 prior comparisons
Capex / revenue moved 38 bp higher
Capex / revenue changed +38 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
2.10%→2.48%2 prior comparisons
Total assets increased 6.2%
Total assets changed +6.2% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
$17.1B→$18.1B4 prior comparisons
Capital expenditure increased 21.8%
Capital expenditure changed +21.8% from the comparable as-filed period.
$78.0M→$95.0M2 prior comparisons
Operating cash flow / net income decreased 22.4%
Operating cash flow / net income changed -22.4% from the comparable as-filed period.
1.58→1.232 prior comparisons
Shares outstanding decreased 3.5%
Shares outstanding changed -3.5% from the comparable as-filed period. The change ranks at the 0th percentile of 8 prior comparable changes.
178,205,295→171,986,9178 prior comparisons
Research & development decreased 15.3%
Research & development changed -15.3% from the comparable as-filed period.
$137.0M→$116.0M2 prior comparisons
Net income increased 1.2%
Net income changed +1.2% from the comparable as-filed period.
$245.0M→$248.0M2 prior comparisons
R&D / revenue moved 66 bp lower
R&D / revenue changed -66 basis points from the comparable as-filed period.
3.69%→3.03%2 prior comparisons
Selling, general & administrative increased 2.6%
Selling, general & administrative changed +2.6% from the comparable as-filed period.
$303.0M→$311.0M2 prior comparisons
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.